Cyramza is an FDA approved drug that is prescribed to treat advanced gastric cancer and non-small cell lung cancer. Cyramza is a cancer medication known as a vascular endothelial growth factor or VEGF receptor 2 antagonist. This drug works by blocking the blood supply to tumors in a patient. Cyramza contains a boxed warning regarding the increased risk of hemorrhage that could also lead to severe events. Doctors are advised to stop Cyramza treatment if the patient experiences severe bleeding.